Regoli D, Rhaleb N E, Dion S, Tousignant C, Rouissi N, Jukic D, Drapeau G
Department of Pharmacology, Medical School, University of Sherbrooke, Canada.
Pharmacol Res. 1990 Jan-Feb;22(1):1-14. doi: 10.1016/1043-6618(90)90738-y.
Discovered in 1983, the decapeptide neurokinin A has been shown to occur in several peripheral organs and to exert a variety of biological effects. In this article, we review the most sensitive and selective in vivo and in vitro tests which have been used in various laboratories to evaluate naturally occurring or synthetic neurokinin A. A comparison of the effects of neurokinin A and those of its mammalian homologues, substance P and neurokinin B as well as those of tachykinins and related peptides is presented in the frame of a study directed toward characterization of neurokinin receptors. Indeed, neurokinin A has been shown to be particularly active on a neurokinin receptor subtype, the NK-2. Structure-activity studies performed with neurokinin A and its fragments as well as with several analogues of both the decapeptide and the heptapeptide NKA(4-10) have brought to the identification of the minimum structure required for activation of NK-2 receptors. Selective agonists for this receptor have been identified, in particular [Nle10]-NKA(4-10) and [beta-Ala8]-NKA(4-10).
十肽神经激肽A于1983年被发现,已证实它存在于多个外周器官中,并具有多种生物学效应。在本文中,我们综述了各个实验室用于评估天然或合成神经激肽A的最灵敏和最具选择性的体内和体外试验。在一项旨在鉴定神经激肽受体的研究框架内,对神经激肽A及其哺乳动物同源物P物质和神经激肽B以及速激肽和相关肽的作用进行了比较。事实上,神经激肽A已被证明对神经激肽受体亚型NK-2具有特别的活性。用神经激肽A及其片段以及十肽和七肽NKA(4-10)的几种类似物进行的构效关系研究,已确定了激活NK-2受体所需的最小结构。已鉴定出该受体的选择性激动剂,特别是[Nle10]-NKA(4-10)和[β-Ala8]-NKA(4-10)。